Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates
ConditionLung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCreo Medical Limited
About this trial
The overall purpose of this study is to characterise the clinical safety and performance of the Creo Medical MicroBlate™ Flex AB1 instrument in patients with pathologically confirmed malignancy eligible for surgical resection of their nodule, receiving bronchoscopic ablation prior to surgery.
Eligibility criteria
Qualifiers
Have signed informed consent.
Subject is willing and able to comply with all aspects of the treatment and evaluation schedule.
Are ≥ 18 years old.
Have lung lesion(s)/nodule(s) which are histopathological-confirmed as cancer.
Disqualifiers
Have target nodule(s) within the International Association for the Study of Lung Cancer (IASLC) "Central Zone" (including bronchial tree, major vessels, heart, oesophagus, spinal cord, and phrenic & laryngeal nerves).
Are pregnant or breast feeding, as determined by standard site practices.
Have participated in an investigational drug or device research study within 30 days of enrolment that would interfere with this study.
Have a physical or psychological condition that would impair study participation or jeopardise the safety or welfare of the subject.
Trial design
Treatments tested in this trial
- Ablation
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov